NCT06055907招募中不适用
Anti-Xa Activity in Patients Receiving Different Vasopressors.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Anti-Xa activity
研究概览
简要总结
Critically ill patients require antithrombotic prophylaxis. At the same time, majority of them is receiving various vasopressors. The aim of the study is to determine whether there is a difference in anti-Xa activity, which is a marker of anti thrombotic activity of low molecular weight heparins, between the patients receiving norepinephrine with argipressin, compared to those receiving norepinephrine alone.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Circulatory failure
- •Supported by continuous infusion of noradrenaline or noradrenaline and argipressin
- •Receiving subcutaneous dalteparin for the prevention of venous thromboembolism.
排除标准
- •Contraindications for dalteparin
- •Severe coagulopathy
- •Acute or subacute bacterial endocarditis
- •Pregnant women
- •BMI (body mass index) > 30kg/m2
- •Chronic kidney disease with eGFR (estimated glomerular filtration rate) < 30 ml/min/1.73 m2
- •Renal replacement therapy
- •The patient died within 52 hours of starting VTE (venous thromboembolism) prophylaxis with dalteparin
结局指标
主要结局
Anti-Xa activity
时间窗: 4 hours after third dose
IU anty-Xa/ml
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Anti-Xa Levels in Critically Ill Patients Receiving Low-molecular-weight Heparin for Thromboprophylaxis in ChinaCritically IllAnti-XaNCT03311984Southeast University, China200
已完成
不适用
Is Anti-Factor Xa Associated With Outcome in Patients With Critical COVID-19 on Low-Molecular-Weight Heparin?Covid19ThromboembolismBleedingNCT05256524Karolinska Institutet1,520
已完成
4 期
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery DiseaseCoronary Artery DiseaseNCT04006288University of Florida90
已完成
不适用
Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 PatientsCovid-19Thromboembolic EventsBleedingNCT04412304Karolinska Institutet166
已完成
不适用
Anti-factor Xa Based Venous Thromboembolism ProphylaxisDose Adjustment of Enoxaparin in ICU PatientsNCT05221879Meir Medical Center75